Sheppard Mullin Advises Unicycive Therapeutics in $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb®
The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $130 million private placement.
The funding is being led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and is supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc.
The deal was led by Jeff Fessler, co-leader of Sheppard Mullin’s Life Sciences Industry Team and associate Seth Lemings.
Click here to read the press release.